CAPR
HEALTHCARECapricor Therapeutics Inc
$34.38+1.42 (+4.31%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CAPR Today?
No stock-specific AI insight has been generated for CAPR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$4.30$40.37
$34.38
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-2.26
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding57.8M
CAPR News
20 articles- A Look At Capricor Therapeutics (CAPR) Valuation After Phase 3 HOPE-3 Duchenne Data And FDA Review ProgressYahoo Finance·May 9, 2026
- Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12Yahoo Finance·May 4, 2026
- How Phase 3 HOPE-3 DMD Data And BLA Review At Capricor Therapeutics (CAPR) Has Changed Its Investment StoryYahoo Finance·Apr 24, 2026
- We're Not Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash BurnYahoo Finance·Apr 24, 2026
- Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual MeetingYahoo Finance·Apr 22, 2026
- Caprock Intersects 38.48 g/t Au over 1.6m Included Within a Broader Interval of 2.84 g/t over 23.2m at DestinyYahoo Finance·Mar 25, 2026
- Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp.Yahoo Finance·Mar 23, 2026
- Capricor Therapeutics (CAPR) Reports Positive Phase 3 HOPE-3 Data and $318M 2025 Cash BalanceYahoo Finance·Mar 18, 2026
- Is It Too Late To Reassess Capricor Therapeutics (CAPR) After Its Recent 130% Surge?Yahoo Finance·Mar 14, 2026
- Capricor Therapeutics Inc (CAPR) Q4 2025 Earnings Call Highlights: FDA Milestones and Financial ...Yahoo Finance·Mar 13, 2026
- Capricor (CAPR) Q4 2025 Earnings Call TranscriptMotley Fool·Mar 13, 2026
- Capricor Therapeutics Q4 Earnings Call HighlightsMarketbeat·Mar 12, 2026
- Capricor: Q4 Earnings SnapshotYahoo Finance·Mar 12, 2026
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Mar 12, 2026
- Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular DystrophyYahoo Finance·Mar 12, 2026
- Capricor Therapeutics, Inc. Q4 2025 Earnings Call SummaryMoby·Mar 12, 2026
- Sector Update: Health Care Stocks Decline Late AfternoonYahoo Finance·Mar 10, 2026
- Sector Update: Health Care Stocks Mixed Tuesday AfternoonYahoo Finance·Mar 10, 2026
- Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLAYahoo Finance·Mar 10, 2026
- Assessing Capricor Therapeutics (CAPR) Valuation After A Strong Short Term Share Price RunYahoo Finance·Mar 10, 2026
All 20 articles loaded
Price Data
Open$33.50
Previous Close$32.96
Day High$33.59
Day Low$30.82
52 Week High$40.37
52 Week Low$4.30
52-Week Range
$4.30$40.37
$34.38
Fundamentals
Market Cap$2.0B
P/E Ratio—
EPS$-2.26
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume711K
Avg Volume (10D)—
Shares Outstanding57.8M
About Capricor Therapeutics Inc
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapies for the treatment and prevention of a broad spectrum of diseases. The company is headquartered in Beverly Hills, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—